ID
22328
Descrição
A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, This form is to be performed in/after Screening Period 1, Weeks 2, 1 Month +/- 3 Days, 2 Months, 4 Months, 6 Months +/- 1 week, 8 Months, 10 Months, 12 Months +/- 1 week and Follow Up. Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1
Link
https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1
Palavras-chave
Versões (2)
- 30/05/2017 30/05/2017 -
- 30/05/2017 30/05/2017 -
Transferido a
30 de maio de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Dosing and Compliance Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Dosing and Compliance Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Similar models
Dosing and Compliance Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
C0011008 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C0040223 (UMLS CUI [2,2])
C0237753 (UMLS CUI [1,2])
C1321605 (UMLS CUI-2)
C0304229 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])